



**The lipid phase preference of the adenosine A2A receptor depends on its ligand binding state**

Journal:	<i>ChemComm</i>
Manuscript ID	CC-COM-12-2018-010130.R1
Article Type:	Communication

SCHOLARONE™  
Manuscripts



## The lipid phase preference of the adenosine A<sub>2A</sub> receptor depends on its ligand binding state

[a] M. Gertrude Gutierrez, [a] Jacob Deyell, [a] Kate White, [a] Lucia C. Dalle Ore, [b] Vadim Cherezov, [b] Raymond C. Stevens, and [a,c,d] Noah Malmstadt\*

Received 00th January 20xx,  
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/chemcomm

**Giant unilamellar protein vesicles (GUPs) were formed with the adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R) incorporated in the lipid bilayer and observed protein partitioning into liquid ordered and liquid disordered phases. When no ligand is bound, A<sub>2A</sub>R partitions preferentially into the liquid disordered phase of GUPs, while ligand-bound A<sub>2A</sub>R partitions into the liquid ordered phase.**

Lipid rafts are hypothesized areas on the cell plasma membrane where cholesterol, sphingolipids, and proteins may aggregate in a manner that modulates cellular signaling.<sup>[1-4]</sup> In recent decades, lipid rafts have been modeled extensively using phase-separating giant unilamellar vesicles (GUVs).<sup>[5, 6]</sup> GUVs allow for stringent control of membrane composition and direct observation of micron-scale lipid phase separation that mimics the hypothetical rafts.<sup>[4, 6, 7]</sup> GUVs of certain ternary lipid compositions can undergo liquid-liquid (L-L) phase separation where the liquid ordered (l<sub>o</sub>) phase (analogous to lipid rafts) is rich in cholesterol, saturated lipids and sphingolipids, and the liquid disordered phase (l<sub>d</sub>) is enriched in unsaturated lipids.<sup>[8, 9]</sup> Protein incorporated GUVs, known as giant unilamellar protein-vesicles (GUPs), offer a means to directly observe protein partitioning in phase-separating GUP compositions. Our group has previously reported on the partitioning of spinach aquaporin SoPIP2;1 and the human serotonin receptor 5-HT<sub>1A</sub>R in phase-separating GUPs.<sup>[10, 11]</sup> Here we report on the phase-separating behavior of the G protein-coupled receptor (GPCR) adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R) in GUPs and observe changes in its partitioning due to ligand binding.

GPCRs are the largest family of proteins in the human genome and are the target of over half of medical therapies on the

market.<sup>[12]</sup> They participate in intracellular signaling cascades and are implicated in behavioral and psychiatric disorders. In particular, A<sub>2A</sub>R is implicated in addiction, in respiratory diseases such as chronic obstructive pulmonary disease (COPD) and is a target for Parkinson's disease therapies.<sup>[13, 14]</sup> Furthermore since A<sub>2A</sub>R participates in immunological feedback loops, this receptor is being targeted for anti-tumor immunotherapies.<sup>[15]</sup> Assisted by the growing number of structural studies on ligand-bound A<sub>2A</sub>R, novel drug candidates are being developed and it has been shown that A<sub>2A</sub>R has a cholesterol consensus motif.<sup>[16, 17]</sup> Biochemical analysis and crystal structures of A<sub>2A</sub>R and other GPCRs have revealed significant changes in helix conformation depending on binding partners including ligands, G proteins, ions, and lipids.<sup>[18-23]</sup> Despite this, studies regarding the biophysical interactions of A<sub>2A</sub>R and the lipid bilayer of the plasma membrane remain scant.<sup>[24, 25]</sup> To better understand the biophysics of A<sub>2A</sub>R phase partitioning, we incorporated A<sub>2A</sub>R in phase separating vesicles made of 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-*sn*-glycero-3-phosphocholine (DPPC) and cholesterol (chol) using a hydrogel-assisted method.<sup>[10, 11]</sup> This work focuses on a single membrane protein, A<sub>2A</sub>R, and uniquely addresses lipid-protein interactions. We investigated ligand-bound and ligand-unbound A<sub>2A</sub>R in purified and crude form and observed that A<sub>2A</sub>R not bound to ligand partitioned to the l<sub>d</sub> phase while agonist- or antagonist-bound A<sub>2A</sub>R partitioned into the l<sub>o</sub> phase. Further we observed that ligand-bound A<sub>2A</sub>R protein concentration in the l<sub>o</sub> phase was unaffected by the area of l<sub>o</sub> domains (A<sub>o</sub>) in GUPs.

Two forms of A<sub>2A</sub>R were used in our investigations: purified protein (pA<sub>2A</sub>R) expressed in Sf9 insect cells and protein from crude membranes fragments (cA<sub>2A</sub>R) expressed in HEK-293 cells and purchased from Perkin Elmer (see SI).<sup>[18]</sup> Throughout this

<sup>a</sup> Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, California 90089, USA


<sup>b</sup> Departments of Biological Sciences and Chemistry, Bridge Institute, University of Southern California, Los Angeles, CA 90089, USA

<sup>c</sup> Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA

<sup>d</sup> Department of Chemistry, University of Southern California, Los Angeles, CA 90089 USA

\*E-mail contact: malmstadt@usc.edu

Supporting information for this article is given via a link at the end of the document. See DOI: 10.1039/x0xx00000x




**Figure 1.** A) GUPs with incorporated  $A_{2A}R$  show protein segregation to certain regions of vesicles. The top set of micrographs shows  $pA_{2A}R(An)$  tagged with rhodamine-labeled antibody. The bottom set of micrographs shows apo  $cA_{2A}R$  tagged with rhodamine-labeled antibody. For  $pA_{2A}R(An)$ , as mol% chol increases, the bright area of the GUP increases, while for  $cA_{2A}R$ , as mol% chol increase, the dark area of the GUP increases. All scale bars are 5  $\mu m$ . B) %Light area of GUP versus mol% of chol. On average 8 GUPs were analyzed per sample with each experiment being repeated 4 times. The error bars indicate standard error of the mean. In rhodamine-labeled antibody-tagged GUP samples with ligand-bound  $A_{2A}R$ , %light area increases with increasing mole percent chol. However, in unbound protein,  $cA_{2A}R$ , %light area decreases with increasing mole percent chol. This shows a protein partitioning dependence on ligand binding state.

work, agonist-bound protein will be identified with (Ag) and antagonist-bound protein will be identified with (An). Protein purified from Sf9 cells (as described in the SI) was solubilized in a 0.01%/0.002% dodecyl- $\beta$ -D-maltoside (DDM)/cholesterol hemisuccinate (CHS), 25 mM HEPES buffer at pH 7.5 and then subsequently bound to 100  $\mu M$  ZM241385 antagonist ( $pA_{2A}R(An)$ ).  $pA_{2A}R$  purity were determined using analytical aSEC, and proper protein incorporation in GUPs was confirmed by radioligand binding (Figure S1). Unbound apo  $cA_{2A}R$ , agonist bound ( $cA_{2A}R(Ag)$ , final concentration N-ethyl-carboxyadenosine (NECA) 100  $\mu M$ ) and antagonist bound ( $cA_{2A}R(An)$ , final concentration ZM241385 100  $\mu M$ ) were used to identify ligand effects on protein partitioning. Both forms of  $A_{2A}R$  were tagged using a rhodamine-labeled monoclonal antibody prior to incorporation in unilamellar GUPs for observations (fluorescence intensity controls, phase partitioning, antibody binding controls and apo and ligand controls and other controls are shown in Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7 and Table S1 and Table S2). Antibody-labeled  $A_{2A}R$  was incorporated in GUPs made from lipid compositions at various DOPC:DPPC:chol ratios (Table S2). All compositions are known to phase separate into  $l_o$  and  $l_d$  phases.<sup>[8]</sup> In all cases, the protein:lipid molar ratio was  $\sim 1:155$  (See SI). The concentration of chol was increased over several GUP trials to identify  $l_o$  and  $l_d$  areas; since  $l_o$  regions are chol-rich, the total  $l_o$  area will increase with increasing chol

concentration. GUPs were formed using the agarose hydration method for protein incorporation as described in the SI. Upon formation, GUPs were harvested by gentle pipetting, settled in an isosmotic glucose buffer and then transferred to observation chambers for viewing using confocal microscopy and subsequently analyzed (Figure S8). Vesicles were anchored to glass microscope slides via biotinylation for ease of imaging (see SI).


In all cases, the antibody-labeled protein segregated preferentially to certain regions of the GUP, indicating that it was participating in phase separation (See Figure 1). The only dye in this system was conjugated to the  $A_{2A}R$  antibody. To identify the  $l_o$  and  $l_d$  phases of GUPs with  $pA_{2A}R(An)$ , apo  $cA_{2A}R$ ,  $cA_{2A}R(An)$ , and  $cA_{2A}R(Ag)$ , we quantified the ratio of bright area versus dark area in Z-stack projections of GUP confocal images while varying chol concentration (see SI Figure S3 for analysis). DOPC:DPPC:chol GUPs with concentrations of chol from 20 to 40 mol% were prepared. In GUPs containing  $A_{2A}R$  bound to ligand, the bright areas increase with increasing chol content while in those containing apo  $cA_{2A}R$  the bright areas decrease with increasing chol (Figure 1). The micrographs in Figure 1 show phase separating GUPs with varying amounts of chol. Since chol concentration positively correlates with percent area of the  $l_o$  phase ( $A_o$ ) we concluded that ligand-bound  $pA_{2A}R(An)$ ,  $cA_{2A}R(An)$ , and  $cA_{2A}R(Ag)$  partitions to the  $l_o$  phase while ligand-unbound  $cA_{2A}R$  partitions to the  $l_d$  phase. Furthermore, protein



**Figure 2.** Partition coefficient ( $K$ ) versus area of liquid ordered domain. All proteins investigated, bound and unbound, have a negative slope. The shaded areas around the lines show the goodness of fit.

partitioning is independent of CHS or DDM because  $cA_{2A}R$  solubilized in either CHS or CHS/DDM (similar conditions to  $pA_{2A}R$ ) consistently partitions to the  $l_d$  phase (Figure S9 and Figure S10).

Ligand-bound  $A_{2A}R$  partitioning to the  $l_o$  phase of phase-separating mixtures of GUPs could be due to changes in protein conformation or dynamics when ligand is bound to the GPCR. While previous reports on GPCR protein partitioning have prominently shown partitioning into the  $l_d$  phase of phase separating lipid bilayers,<sup>[10, 11]</sup> some results have suggested that ligand binding with GPCRs causes co-segregation into lipid rafts.<sup>[26, 27]</sup> For example, in investigations isolating caveolae (which tend to associate with raft-like lipid compositions) from plasma membranes, subfractionation of caveolae and immunofluorescence have shown the G protein subunits  $G_{\alpha i}$  and  $G_{\alpha s}$  in these lipid rafts,<sup>[28]</sup> and the adenosine A1A GPCR has been shown to move into and out of these lipid rafts.<sup>[29]</sup> The lipid raft hypothesis suggests that proteins and signaling components aggregate into dynamic lipid rafts to strengthen signaling pathways and to avoid signaling protein cross-talk and degradation.<sup>[27, 30]</sup> While protein behavior in a cell plasma membrane will depend on protein-protein and protein-cytoskeleton interactions, GPCRs are known to undergo conformational changes during ligand binding and activation that change the receptor's microenvironment in the plasma membrane.<sup>[31-33]</sup> Our results suggest and support theories on the dynamic aggregation of protein signaling components into cellular lipid rafts, which may be triggered by agonist binding. GPCR functionality and membrane elasticity also support liquid ordered phase partitioning of  $A_{2A}R$ . Most of this research has been done on rhodopsin and Garwisch et al. showed that rhodopsin could induce lipid order by hydrophilic matching phenomenon,<sup>[34]</sup> and this was further supported by MD



**Figure 3.** Fluorescence intensity change as a function of time for  $A_{2A}R$ -incorporating GUPs incubated with a fluorescent GTP analog and stimulated by agonist. The  $A_{2A}R$  was reconstituted from crude membrane fragments which also include the relevant G protein. The experiment was performed at two chol concentrations; higher activity was observed at higher chol concentration. These data show single exponential rates and the standard error mean of 6 replicates at each chol concentration.

simulations performed by Grossfield and coworkers.<sup>[35]</sup> Further research by Garwisch and coworkers has shown that elastic curvature stress of the lipid bilayer favors the active meta-II state of rhodopsin.<sup>[36, 37]</sup> A similar effect was observed by Brown and coworkers, who argued that the conformation energetics of the protein are linked to the continuum mechanical properties of the lipid bilayer.<sup>[38]</sup>

We have also observed that 5-HT<sub>1A</sub>R, is more active in ordered membranes.<sup>[39]</sup> Therefore it is not surprising that ligand-bound  $A_{2A}R$  is observed here to partition into ordered domains in phase separating membranes.

To further assess protein partitioning, a partition coefficient  $K$  was calculated:  $K=i_o/i_d$  where  $i_o$  is the fluorescence intensity (a.u.) of the  $l_o$  area and  $i_d$  is the fluorescence intensity (a.u.) of the  $l_d$  area. As shown in Figure 2,  $K$  plotted against  $A_o$  has a negative slope for all samples. As  $A_o$  increased, the ratio of  $i_o/i_d$  decreased, indicating a decrease in the fluorescence intensity of the  $l_o$  area (Figure 2). Furthermore for all ligand-bound samples,  $K$  values were greater than 1, whereas for ligand-unbound apo  $cA_{2A}R$ , the  $K$  values were less than 1. The observed  $K$  values for ligand-unbound  $cA_{2A}R$  is due to its opposite partitioning behavior. Without ligand bound, the protein partitions into the liquid disordered phase as described above and in the SI (SI control images).  $K$  values for ligand-unbound crude protein controls in 0.01% CHS or 0.01%/0.002% CHS/DDM are shown in Figure S10 and have the same trends as  $cA_{2A}R$  in Fig 2. These results show that ligand-bound protein preference for the  $l_o$  phase decreases as chol concentration increases in GUPs and because the trends in Figure 2 do not cross  $y=1$  suggests that GPCR partitioning is independent of the size of the  $l_o$  phase,  $A_o$ . In serotonin, rhodopsin, and  $\beta$ -adrenergic receptors, chol modulation and binding affects the orientation and population of receptor oligomers.<sup>[40-42]</sup> Thus spatial arrangement of GPCRs, including dimerization and oligomerization, in the plasma membrane may be mediated by lipid interactions. The decrease observed in  $K$  with increasing chol concentration may be related to such spatial organizational effects. Note that this effect is least pronounced (to the point of being nearly unobservable) for the  $cA_{2A}R(\text{An})$  sample. This could be due to interactions with endogenous lipids introduced in the crude membrane fragments.

To demonstrate that membrane-incorporated A<sub>2A</sub>R is biochemically active, we measured the activity of A<sub>2A</sub>R incorporated from crude membrane fragments into GUPs. The activity assay was performed as described in Gutierrez et al 2016,<sup>[39]</sup> where GUPs were formed to encapsulate BODIPY-GTPγS. Upon formation and settling, GUPs were incubated with the agonist NECA and fluorescent intensity increase due to receptor-catalyzed BODIPY-GTPγS binding to the Gα subunit of the G protein was tracked over time via microplate reader (Figure 3). This experiment was performed in GUPs made from two ratios of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) to chol. The protein is active at both chol concentrations, but receptor-catalyzed nucleotide exchange is faster at the higher chol concentration. The fact that the receptor is capable of catalyzing GDP-GTP exchange subsequent to reconstitution in GUPs demonstrates that the phase segregation phenomenon reported here reflects the behavior of a correctly folded, biologically active protein.

The results here show that the behavior of the GPCR A<sub>2A</sub>R depends on lipid composition. Effects of lipid composition on GPCR function have been reported for rhodopsin, β<sub>2</sub>-adrenergic receptors, and serotonin receptors.<sup>[1, 22, 34, 36, 39, 43]</sup> For example, increases in chol concentration in lipid bilayers have been reported to increase the functional activity of the serotonin receptor 5-HT<sub>1A</sub>R and initial work on the A<sub>2A</sub>R receptor shows similar behavior (Figure S11).<sup>[39]</sup> Differences in lipid bilayer thickness, ordering, geometry, and pressure differences between l<sub>o</sub> and l<sub>d</sub> phases have also been shown to alter the activity of rhodopsin.<sup>[34, 36, 37]</sup> Differential partitioning into lipid regions with different bulk properties may therefore modulate the functional activity of A<sub>2A</sub>R. This is in addition to the potential of phase segregation to promote the aggregation of signaling components and regulate GPCR degradation and activity.<sup>[1, 43]</sup> Apart from signaling mechanisms linked to putative raft localization, the results here support the idea that lipid ordering preferentially supports ligand-bound configurations of A<sub>2A</sub>R. Phase separating compositions of GUPs incorporated with purified and crude GPCR A<sub>2A</sub>R display l<sub>o</sub> partitioning when ligand is bound and l<sub>d</sub> partitioning when unbound. Preferential partitioning of ligand-bound receptor supports the hypotheses on transient dynamic lipid raft assemblies in the plasma membrane that aggregate for protein signaling and regulation. The interplay between ligand-mediated alterations in protein geometry and preferential location to membrane subcompartments may represent an important signal control mechanism for GPCRs and membrane proteins in general.


MGG was funded by a Viterbi Fellowship, Oakley Fellowship, and ARCS Scholarship. JD was funded by the USC SURE program. LCDO was funded by a Viterbi Fellowship. This work was supported by the Office of Naval Research (N00014-16-1-2382).

### Conflicts of interest

There are no conflicts to declare

### Notes and references

- 1 I. Levental and S.L. Veatch, *J Mol Biol* **2016**, 428.
- 2 K. Simons and J.L. Sampaio, *Cold Spring Harbor perspectives in biology* **2011**, 3.
- 3 L.J. Pike, *Journal of lipid research* **2009**, 50 Suppl.
- 4 E. Sezgin, et al., *Biochimica et biophysica acta* **2012**, 1818.
- 5 O. Wesolowska, et al., *Acta Biochimica Polonica* **2009**, 56.
- 6 C. Dietrich, et al., *Biophysical journal* **2001**, 80.
- 7 E. Sezgin, et al., *Nature protocols* **2012**, 7.
- 8 S.L.K.S.L. Veatch, *Biophysical journal* **2003**, 85, 3074.
- 9 S.L. Veatch and S.L. Keller, *Physical Review Letters* **2005**, 94.
- 10 J.S. Hansen, et al., *Journal of the American Chemical Society* **2013**, 135, 17294.
- 11 M.G. Gutierrez and N. Malmstadt, *Journal of the American Chemical Society* **2014**, 136, 13530.
- 12 R. Zhang and X. Xie, *Acta pharmacologica Sinica* **2012**, 33.
- 13 O. Bonneau, et al., *Am J Physiol Lung Cell Mol Physiol* **2006**, 290.
- 14 M. Cieslak, M. Komoszynski, and A. Wojtczak, *Purinergic Signal* **2008**, 4.
- 15 R.D. Leone, Y.C. Lo, and J.D. Powell, *Comput Struct Biotechnol J* **2015**, 13.
- 16 V. Katritch, V. Cherezov, and R.C. Stevens, *Annu. Rev. Pharmacol. Toxicol.* **2013**, 53, 531.
- 17 [M. Jafurulla, S. Tiwari, and A. Chattopadhyay, *Biochemical and biophysical research communications* **2011**, 404.
- 18 W. Liu, et al., *Science* **2012**, 337.
- 19 F. Xu, et al., *Science* **2011**, 332.
- 20 W. Liu, et al., *Science* **2012**, 337.
- 21 B. Carpenter, et al., *Nature* **2016**, 536.
- 22 M. Zocher, et al., *Proceedings of the National Academy of Sciences of the United States of America* **2012**, 109.
- 23 L. Ye, et al., *Nature* **2016**, 533.
- 24 A. Jazayeri, S.P. Andrews, and F.H. Marshall, *Chem Rev* **2017**, 117.
- 25 G. Lebon, et al., *Nature* **2011**, 474.
- 26 M. Fallahi-Sichani and J.J. Linderman, *PLoS One* **2009**, 4.
- 27 B. Chini and M. Parenti, *Journal of molecular endocrinology* **2004**, 32.
- 28 P.V. Escriba, et al., *Biochimica et biophysica acta* **2007**, 1768.
- 29 R.D. Lasley and E.J. Smart, *Trends in Cardiovascular Medicine* **2001**, 11.
- 30 B. Chini and M. Parenti, *Journal of molecular endocrinology* **2009**, 42.
- 31 J. Barnett-Norris, D. Lynch, and P.H. Reggio, *Life Sci* **2005**, 77.
- 32 V.P. Jaakola, et al., *Science* **2008**, 322.
- 33 F. Xu, et al., *Science* **2011**, 332.
- 34 W.E. Teague Jr., et al., *Faraday Discussions* **2013**, 161.
- 35 L.A. Salas-Estrada, et al., *Biophysical journal* **2018**, 114.
- 36 O. Soubias, et al., *Biophysical journal* **2010**, 99.
- 37 O. Soubias, et al., *Biophysical journal* **2015**, 108.
- 38 A.V. Botelho, et al., *Biochemistry* **2002**, 41.
- 39 M.G. Gutierrez, K. Mansfield, and N. Malmstadt, *Biophysical journal* **2016**, 110, 2486.
- 40 F. Kobe, et al., *Biochimica et biophysica acta* **2008**, 1783.
- 41 U. Renner, et al., *Molecular pharmacology* **2007**, 72.
- 42 V. Cherezov, et al., *Science* **2007**, 318.
- J.H. Lorent and I. Levental, *Chemistry and physics of lipids* **2015**, 192.



As cholesterol fraction increases, ligand-bound receptor occupies more vesicle surface area, demonstrating co-localization with the cholesterol-rich phase.